A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET).

The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to <18 years of age with somatostatin receptor (SSTR)-positive tumors.

Start Date01 Jan 2025

Sponsor / Collaborator

ITM Solucin GmbH

NCT06455358

/ Not yet recruitingPhase 1/2IIT

61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors: The COPPER PET in NET Study A Prospective, Open-label, Randomized, Controlled, Single Centre, Phase I/II PET/CT Study

The goal of this monocentric, open-label, randomized-controlled, reader-blind clinical study is to assess the safety of the radiolabeled somatostatin receptor ligand, 61Cu-NODAGA-LM3, and its sensitivity in comparison to the standard of care, 68Ga-DOTATOC, for PET/CT imaging in patients with well differentiated bronchopulmonary and gastroenteropancreatic neuroendocrine tumors.

Start Date01 Jan 2025

Sponsor / Collaborator

Universitätsspital Basel

NCT06510868

/ Not yet recruitingNot ApplicableIIT

Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy

This is a prospective observational study which aims to identify individuals predisposed to developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) could improve patient outcomes in different ways. First, it will enable improved patient selection for PRRT where alternative treatment options are available. Second, understanding the final pathway and how it is modulated by PRRT could allow the design of strategies to halt this process. Third, while it is unknown whether the development of MDS and AML is a late effect of radiopharmaceuticals in general or it is confined to cancer populations or specific radioisotopes will need to be confirmed. Finally, understanding this devastating complication is expected to be the cornerstone towards advancing radiopharmaceuticals' role in the adjuvant setting.

Start Date01 Aug 2024

Sponsor / Collaborator

University Health Network

100 Clinical Results associated with Gastric Neuroendocrine Tumor

100 Translational Medicine associated with Gastric Neuroendocrine Tumor

0 Patents (Medical) associated with Gastric Neuroendocrine Tumor

820

Literatures (Medical) associated with Gastric Neuroendocrine Tumor

03 Jan 2025·Gut and Liver

Clinical Characteristics and Long-term Outcomes of Gastric Neuroendocrine Tumors

Article

Author: Cho, Soo-Jeong ; Zheng, Quanxin ; Kim, Sang Gyun ; Chung, Hyunsoo ; Kim, Ji Yoon

Background/AimsGastric neuroendocrine tumors (GNETs), once rare, have become more prevalent due to the increased use of endoscopy and increased physician awareness. The clinical characteristics and long-term outcomes of GNET management were explored in this study.MethodsThe clinical data of 69 patients who treated at Seoul National University Hospital between January 2013 and October 2023 were retrospectively studied. Baseline characteristics, recurrence rates, associated factors, and overall survival rates were analyzed.ResultsOf the tumors, 71.0% were grade 1, 24.6% were grade 2, 1.4% were grade 3, and 2.9% were poorly differentiated. In terms of tumor type, 69.6% were type I, 1.4% were type II, and 29.0% were type III. A significant proportion of patients with grade 1 tumors received more endoscopic treatment, whereas a significant proportion of patients with grade 2 tumors underwent surgery or chemotherapy (p=0.015). The overall 5-year survival and recurrence rates were 93.8% and 7.25% (5/69), respectively. Among five patients who experienced recurrence, three had metachronous recurrence, all of which were type I; the remaining two patients exhibited distant hepatic metastasis, encompassing types I and III. The time to recurrence was 1 to 9.8 years. Margin positivity (p=0.002) and invasion deeper than the submucosal layer (p=0.007) were associated with higher recurrence rates. However, there was no significant association between recurrence and intestinal metaplasia, atrophic gastritis, or Helicobacter pylori infection.ConclusionsMost patients with GNETs in this study had grade I and type I tumors, and the overall prognosis was favorable. Patients with risk factors for recurrence warrant further investigation. Those presenting margin positivity or deep invasion after resection should be closely monitored and undergo follow-up examinations, as necessary.

01 Jan 2025·Translational Oncology

Identification and validation of serum MUC17 as a non‐invasive early warning biomarker for screening of gastric intraepithelial neoplasia

Article

Author: Huang, Xiuhong ; Ji, Chenguang ; Liu, Li ; He, Yujian ; Yang, Bingxue ; Yin, Kaige ; Jin, Xiaoxu ; Xie, Xiaoli ; Feng, Zhijie

BACKGROUNDThe early diagnosis and treatment of Gastric Intraepithelial Neoplasia (GIN) are pivotal for improving the survival rates of patients with gastric cancer (GC). Regrettably, reliable noninvasive biomarkers for GIN screening are currently lacking.METHODSmRNA data from the GEO database, pan-cancer data from the TCGA database, and a gene list of exocrine proteins were subjected to integrated analysis to identify a noninvasive biomarker for GIN. The scRNA-seq data analysis, IHC and Elisa were employed to validate the expression of the biomarker in the serum and tissues of clinical patients across different pathological stages.RESULTSMUC17 has been identified as a non-invasive diagnostic marker for GIN. It is upregulated in GIN prior to the onset of gastric carcinogenesis and downregulated in other tumors, with high GC specificity. The area under the curve values of serum MUC17 for differentiating chronic gastritis (CG) from low-grade intraepithelial neoplasia (LGIN), high-grade intraepithelial neoplasia (HGIN), and early gastric cancer (EGC) were 0.8788, 0.8544, and 0.9513, respectively. Additionally, low plasma MUC17 levels were found to be significantly lower in gastric ulcer (GU), gastric neuroendocrine tumor (GNET), and gastrointestinal stromal tumor (GIST) compared to GIN. The AUC for differentiating between GIN and GU, GNET, or GIST was 0.7803, 0.9244 and 0.9796, respectively.CONCLUSIONSThese findings suggest that plasma MUC17 levels hold substantial promise as a screening biomarker for individuals with GIN and EGC, effectively identifying high-risk groups that necessitate further gastroscopy.

01 Jan 2025·Gastric Cancer

Prognostic significance of tertiary lymphoid structures in gastric neuroendocrine carcinoma with association to delta-like ligand 3 and neuroendocrine expressions

Article

Author: Jeong, Seo-Rin ; Song, In Hye ; Escorcia, Freddy E ; Kim, Joo Young ; Hong, Seung-Mo ; Cho, HyungJun ; Jun, Sun-Young ; Ahn, Bokyung ; Park, Young Soo ; Kim, Mi-Ju ; Kim, Deokhoon ; Chung, Joon-Yong ; Hong, Soon Auck

BACKGROUNDGastric neuroendocrine carcinomas (NECs) are rare cancers with highly aggressive behavior. Although tertiary lymphoid structures (TLSs) are well-known prognostic factors in various cancers, their role in gastric NECs remain unexplored. Unique immunohistochemical subtypes of pulmonary NECs have been discovered, however, their feasibility in gastric NECs is unknown.METHODSThe presence and maturation of TLSs (lymphoid aggregates, primary and secondary follicles) were assessed in 48 surgically resected gastric NECs and were compared with immunohistochemical subtypes, using a panel of ASCL1, NeuroD1, POU2F3, YAP1, and DLL3 with three neuroendocrine (NE) markers.RESULTSPatients with secondary follicles had significantly better overall survival (OS) and recurrence-free survival (RFS; both, p = 0.004) than those without them. Based on the hierarchical clustering, gastric NECs were classified into all low/negative (31%), high-YAP1 (19%), high-DLL3/low-NE (29%), and high-NE (21%) expression groups. The high-DLL3/low-NE group was associated with absent TLSs (p = 0.026) and showed the worst OS (p = 0.026). Distant metastasis and a lack of secondary follicles were poor independent prognostic factors of OS and RFS.CONCLUSIONThe assessment of TLSs is a feasible and potent biomarker for gastric NECs, thus enabling better prognosis and more effective immunotherapy. Furthermore, gastric NECs can be categorized as four immunohistochemically distinct groups, of which the high-DLL3/low-NE group has the worst OS with lack of TLSs.

News (Medical) associated with Gastric Neuroendocrine Tumor

05 May 2021

·www.globenewswire.com

The Plethora of Clinical Trials Explore Gastric Cancer Treatments: A Status Review by DelveInsight

Los Angeles, USA, May 04, 2021 (GLOBE NEWSWIRE) -- The Plethora of Clinical Trials Explore Gastric Cancer Treatments: A Status Review by DelveInsight The Gastric Cancer pipeline will allow the treatment space to become more diverse. Many dominant players assess their drug candidates, such as HER2 t-hank, BOLD 100, DKN-01, Abemaciclib, IBI308, Fruquintinib, Zolbetuximab, SHR 1210, Sintilimab, HX 008, Pamiparib, Tislelizumab, HLX10, HER-Vaxx, Margetuximab, Cabozantinib, RC48-ADC, Futibatinib, Poziotinib, Bemarituzumab, and others that are in different phases of development. DelveInsight’s “Gastric Cancer Pipeline Insight” report provides comprehensive insights about 240+ companies and 260+ pipeline drugs in the Gastric Cancer pipeline landscapes. It comprises Gastric Cancer pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Gastric Cancer therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Gastric Cancer pipeline products. Some of the key takeaways of the Gastric Cancer Pipeline Report Get an overview of pipeline landscape @ Gastric Cancer Clinical Trials Analysis Gastric Cancer, also called Stomach Cancer, is a heterogeneous disease that demands continued attention and research about prevention, early detection, and novel therapeutic options. Standard treatment for Gastric Cancer comprises Surgery, Endoscopic mucosal resection, Chemotherapy, Radiation therapy, Chemoradiation, Targeted therapy, and Immunotherapy. Targeted therapy is a type of treatment that utilises drugs or other substances to recognize and attack specific cancer cells. Targeted therapies often cause less harm to normal cells than chemotherapy or radiation therapy does. Monoclonal antibodies and multikinase inhibitors are types of targeted therapy utilised in Gastric Cancer treatment. Gastric Cancer Emerging Drugs For further information, refer to the detailed report @ Gastric Cancer Pipeline Therapeutics Scope of Gastric Cancer Pipeline Drug Insight Key Questions regarding Current Gastric Cancer Treatment Landscape and Emerging Therapies Answered in the Pipeline Report Table of Contents Get a customised pipeline report @ Gastric Cancer Drugs Pipeline Report Related Reports DelveInsight's Gastric Cancer - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's Gastric Cancer - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Gastric Cancer in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. DelveInsight' s Gastric Neuroendocrine Tumors - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's Gastric Ulcers - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's Head and Neck cancer (HNC) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding. DelveInsight's Cervical Cancer Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview and comprehension of historical and forecasted epidemiology. DelveInsight’s, “Insulin Glargine– Biosimilar Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in the Insulin Glargine Biosimilars landscape. About DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Portfolio Management Services to understand the competencies, leverage strengths to prioritise strategic goals and understand the market’s current needs.

AntibodyBiosimilarImmunotherapyRadiation TherapyADC

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis